Portal de Periódicos da CAPES

Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group

2022; Springer Science+Business Media; Volume: 41; Issue: 4 Linguagem: Inglês

10.1007/s00345-022-03993-6

1433-8726

Pietro Diana, Tobias Klatte, Daniele Amparore, Riccardo Bertolo, Umberto Carbonara, Selçuk Erdem, Alexandre Ingels, Önder Kara, Laura Marandino, Michele Marchioni, Stijn Muselaers, Nicola Pavan, Angela Pecoraro, Alessio Pecoraro, Eduard Roussel, Riccardo Campi,

Economic and Financial Impacts of Cancer

Abstract Purpose To systematically review studies focused on screening programs for renal cell carcinoma (RCC) and provide an exhaustive overview on their clinical impact, potential benefits, and harms. Methods A systematic review of the recent English-language literature was conducted according to the European Association of Urology guidelines and the PRISMA statement recommendations (PROSPERO ID: CRD42021283136) using the MEDLINE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Risk-of-bias assessment was performed according to the QUality In Prognosis Studies (QUIPS) tool. Results Overall, nine studies and one clinical trials were included. Eight studies reported results from RCC screening programs involving a total of 159 136 patients and four studies reported screening cost-analysis. The prevalence of RCC ranged between 0.02 and 0.22% and it was associated with the socio-demographic characteristics of the subjects; selection of the target population decreased, overall, the screening cost per diagnosis. Conclusions Despite an increasing interest in RCC screening programs from patients and clinicians there is a relative lack of studies reporting the efficacy, cost-effectiveness, and the optimal modality for RCC screening. Targeting high-risk individuals and/or combining detection of RCC with other health checks represent pragmatic options to improve the cost-effectiveness and reduce the potential harms of RCC screening.